Neuropharmacology podcasts

Nature staff discuss how a newly approved orexin-targeting narcolepsy drug could enable therapies for other neurological conditions, and examine human brain organoids that have remained viable for more than five years. The episode connects sleep medicine, therapeutic neuroscience, and long-term models of human brain development.

Jacob Hooker of Sensorium Therapeutics speaks with Rafael Rosengarten about investigating plant-derived compounds for psychiatric and neurological drug development. They discuss ethnobotanical records, knowledge graphs and AI as tools for generating hypotheses, alongside the medicinal chemistry and clinical testing needed to turn potential leads into medicines.

Hosted by Rafael Rosengarten